JP2021530444A5 - - Google Patents

Info

Publication number
JP2021530444A5
JP2021530444A5 JP2020571522A JP2020571522A JP2021530444A5 JP 2021530444 A5 JP2021530444 A5 JP 2021530444A5 JP 2020571522 A JP2020571522 A JP 2020571522A JP 2020571522 A JP2020571522 A JP 2020571522A JP 2021530444 A5 JP2021530444 A5 JP 2021530444A5
Authority
JP
Japan
Prior art keywords
antigen
specifically binds
group
pharmaceutical composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020571522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530444A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039620 external-priority patent/WO2020006312A1/en
Publication of JP2021530444A publication Critical patent/JP2021530444A/ja
Publication of JP2021530444A5 publication Critical patent/JP2021530444A5/ja
Priority to JP2025015837A priority Critical patent/JP2025072462A/ja
Pending legal-status Critical Current

Links

JP2020571522A 2018-06-28 2019-06-27 固形および液体悪性病変における多重car t細胞での複数抗原の標的化 Pending JP2021530444A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015837A JP2025072462A (ja) 2018-06-28 2025-02-03 固形および液体悪性病変における多重car t細胞での複数抗原の標的化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862691486P 2018-06-28 2018-06-28
US62/691,486 2018-06-28
US201862697526P 2018-07-13 2018-07-13
US62/697,526 2018-07-13
PCT/US2019/039620 WO2020006312A1 (en) 2018-06-28 2019-06-27 Targeting of multiple antigens with multiplex car t cells in solid and liquid malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015837A Division JP2025072462A (ja) 2018-06-28 2025-02-03 固形および液体悪性病変における多重car t細胞での複数抗原の標的化

Publications (2)

Publication Number Publication Date
JP2021530444A JP2021530444A (ja) 2021-11-11
JP2021530444A5 true JP2021530444A5 (cg-RX-API-DMAC7.html) 2022-07-04

Family

ID=68987577

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571522A Pending JP2021530444A (ja) 2018-06-28 2019-06-27 固形および液体悪性病変における多重car t細胞での複数抗原の標的化
JP2025015837A Pending JP2025072462A (ja) 2018-06-28 2025-02-03 固形および液体悪性病変における多重car t細胞での複数抗原の標的化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015837A Pending JP2025072462A (ja) 2018-06-28 2025-02-03 固形および液体悪性病変における多重car t細胞での複数抗原の標的化

Country Status (6)

Country Link
US (1) US12466869B2 (cg-RX-API-DMAC7.html)
EP (1) EP3813863A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021530444A (cg-RX-API-DMAC7.html)
CN (1) CN112399852A (cg-RX-API-DMAC7.html)
AU (1) AU2019291882A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020006312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076197A1 (en) 2019-10-15 2021-04-22 Diverse Biotech, Inc. Conjugate molecules
WO2021102142A1 (en) * 2019-11-19 2021-05-27 Oklahoma Medical Research Foundation Okn-007 as a therapeutic agent
WO2022099065A1 (en) * 2020-11-05 2022-05-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Conditional control of universal car t cells through stimulus-reactive adaptors
US20240043544A1 (en) * 2020-12-08 2024-02-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
US11883499B2 (en) 2022-02-01 2024-01-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
US11660348B1 (en) 2022-02-01 2023-05-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
WO2025085511A1 (en) * 2023-10-18 2025-04-24 University Of Washington Systems and methods for polymer-mediated activation of engineered cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2010207133A (ja) * 2009-03-10 2010-09-24 Sony Corp 細胞分離方法
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド,ボルチモア 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
ES2654143T3 (es) 2012-10-02 2018-02-12 Gilead Sciences, Inc. Inhibidores de desmetilasas de histonas
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
US10744207B2 (en) 2014-05-02 2020-08-18 Acepodia, Inc. Biological complexes and methods for using same
RS63601B1 (sr) 2014-10-09 2022-10-31 Univ Yamaguchi Vektor ekspresije car i t ćelije koje eksprimiraju car
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
WO2016168766A1 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
US20180371052A1 (en) 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
CN105504042A (zh) 2016-02-04 2016-04-20 北京艺妙神州医疗科技有限公司 检测car-t细胞的捕获探针、该细胞含量的检测方法及应用
CN108697798A (zh) 2016-02-16 2018-10-23 达纳-法伯癌症研究所有限公司 免疫疗法组合物及方法
US20170274095A1 (en) 2016-03-23 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
EP3529268B1 (en) * 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
ES3024357T3 (en) 2017-02-17 2025-06-04 Purdue Research Foundation Targeted ligand-payload based drug delivery for cell therapy
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
US20200306376A1 (en) * 2017-04-25 2020-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for targeted tumor immunotherapy
CN108490174B (zh) 2018-04-18 2022-06-24 上海尚珞生物医药科技有限公司 检测car-t细胞的方法及其应用
CN108660113A (zh) 2018-05-21 2018-10-16 杭州启澜生物医学技术有限公司 一种制备改良型car-t细胞的方法

Similar Documents

Publication Publication Date Title
JP2020505433A5 (cg-RX-API-DMAC7.html)
TW202313113A (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
JP2008503476A5 (cg-RX-API-DMAC7.html)
JP2022523740A5 (cg-RX-API-DMAC7.html)
JP2018524347A5 (cg-RX-API-DMAC7.html)
JP2019506403A5 (cg-RX-API-DMAC7.html)
JP2012509889A5 (cg-RX-API-DMAC7.html)
JP2013520442A5 (cg-RX-API-DMAC7.html)
JP2014533279A5 (cg-RX-API-DMAC7.html)
JP2011507932A5 (cg-RX-API-DMAC7.html)
JP2014510729A5 (cg-RX-API-DMAC7.html)
JP2023508496A5 (cg-RX-API-DMAC7.html)
AU2018360559A1 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use
JP2022535609A5 (cg-RX-API-DMAC7.html)
JP7761490B2 (ja) 小細胞肺がんの併用療法用キノリン誘導体
JP2026503515A (ja) 非ホジキンリンパ腫治療用医薬組成物及びその使用
JP2022508935A (ja) がん治療における免疫モジュレーションのための組合せ
JP2013504590A5 (cg-RX-API-DMAC7.html)
Lehnert et al. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
JP2015518053A5 (cg-RX-API-DMAC7.html)
JP2023540206A5 (cg-RX-API-DMAC7.html)
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物
JP2021521219A (ja) Bet阻害剤およびプロテアソーム阻害剤を用いる併用療法
TWI912688B (zh) 用於治療三陰性乳癌之藥物組合物